The Chan Zuckerberg Initiative and Innovative Genomics Institute have launched the Center for Pediatric CRISPR Cures with $20 million in funding to develop personalized CRISPR-based therapies for ultra-rare pediatric diseases. Building on the success of the first personalized gene-editing treatment for an infant with a rare metabolic disorder, the Center aims to create reproducible methods to bring gene editing to a broader patient population. Separately, gene therapy biotech CoRegen raised $93.4 million to support manufacturing scale-up and initial clinical trials. Additionally, advances in genome editing using CRISPR-Cas13 are enabling precise correction of disease-causing mutations, including for Hutchinson-Gilford progeria syndrome. These programs illustrate a growing focus on individualized genetic medicines to address severe rare diseases.